Fusilev no longer requires prior authorization

Because Spectrum Pharmaceuticals has stopped manufacturing Fusilev^® (levoleucovorin), HCPCS code J0641, we no longer require prior authorization through AIM Specialty Health^® for dates of service on or after May 31, 2022. The drug was part of members’ medical benefits, not their pharmacy benefits.
This change applies to:

• Blue Cross Blue Shield of Michigan commercial:
• Members who have coverage through fully insured groups
• Members with individual coverage
• UAW Retiree Medical Benefits Trust members with Blue Cross non-Medicare plans
• Medicare Plus Blue℠ members
• Blue Care Network commercial members
• BCN Advantage℠ members

For additional information on requirements related to drugs covered under the medical benefit, refer to the following drug lists:

• Blue Cross and BCN commercial members:
• Medical oncology prior authorization list for Blue Cross commercial fully insured and BCN commercial members
• Blue Cross and BCN utilization management medical drug list
• URMBT members with Blue Cross non-Medicare plans:
• Medical oncology prior authorization list for UAW Retiree Medical Benefits Trust PPO non-Medicare members
• Medical Drug Management with Blue Cross for UAW Retiree Medical Benefit Trust PPO non-Medicare Members

Note: Accredo manages prior authorization requests for additional medical benefit drugs for these members.

• Medicare Plus Blue and BCN Advantage members:
• Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members